Xu X - Search Results

1

Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output.

Zhao Q, Liu J, Deng H, Ma R, Liao JY, Liang H, Hu J, Li J, Guo Z, Cai J, Xu X, Gao Z, Su S. Zhao Q, et al. Among authors: xu x. Cell. 2020 Oct 1;183(1):76-93.e22. doi: 10.1016/j.cell.2020.08.009. Epub 2020 Sep 14. Cell. 2020. PMID: 32931733 Free article.

2

LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.

Zhang Y, Huang YX, Wang DL, Yang B, Yan HY, Lin LH, Li Y, Chen J, Xie LM, Huang YS, Liao JY, Hu KS, He JH, Saw PE, Xu X, Yin D. Zhang Y, et al. Among authors: xu x. Theranostics. 2020 Aug 29;10(23):10823-10837. doi: 10.7150/thno.47830. eCollection 2020. Theranostics. 2020. PMID: 32929382 Free PMC article.

3

Mitochondria-specific delivery system for targeted regulation of mitochondrial gene expression.

Su S, Cao S, Liu J, Xu X. Su S, et al. Among authors: xu x. STAR Protoc. 2021 Jan 15;2(1):100275. doi: 10.1016/j.xpro.2020.100275. eCollection 2021 Mar 19. STAR Protoc. 2021. PMID: 33511358 Free PMC article.

4

Remodeling of Mitochondrial Metabolism by a Mitochondria-Targeted RNAi Nanoplatform for Effective Cancer Therapy.

Xu R, Huang L, Liu J, Zhang Y, Xu Y, Li R, Su S, Xu X. Xu R, et al. Among authors: xu x, xu y. Small. 2024 Mar;20(10):e2305923. doi: 10.1002/smll.202305923. Epub 2023 Nov 2. Small. 2024. PMID: 37919865

5

Nanocarrier-mediated antioxidant delivery for liver diseases.

Li S, Li H, Xu X, Saw PE, Zhang L. Li S, et al. Among authors: xu x. Theranostics. 2020 Jan 1;10(3):1262-1280. doi: 10.7150/thno.38834. eCollection 2020. Theranostics. 2020. PMID: 31938064 Free PMC article. Review.

6

Enhancer-Driven lncRNA BDNF-AS Induces Endocrine Resistance and Malignant Progression of Breast Cancer through the RNH1/TRIM21/mTOR Cascade.

Lin X, Dinglin X, Cao S, Zheng S, Wu C, Chen W, Li Q, Hu Q, Zheng F, Wu Z, Lin DC, Yao Y, Xu X, Xie Z, Liu Q, Yao H, Hu H. Lin X, et al. Among authors: xu x. Cell Rep. 2020 Jun 9;31(10):107753. doi: 10.1016/j.celrep.2020.107753. Cell Rep. 2020. PMID: 32521278 Free article.

7

Dual Hypoxia-Targeting RNAi Nanomedicine for Precision Cancer Therapy.

Li Y, Ding J, Xu X, Shi R, Saw PE, Wang J, Chung S, Li W, Aljaeid BM, Lee RJ, Tao W, Teng L, Farokhzad OC, Shi J. Li Y, et al. Among authors: xu x. Nano Lett. 2020 Jul 8;20(7):4857-4863. doi: 10.1021/acs.nanolett.0c00757. Epub 2020 Jun 8. Nano Lett. 2020. PMID: 32479088 Free PMC article.

8

LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer.

Xu Y, Ren W, Li Q, Duan C, Lin X, Bi Z, You K, Hu Q, Xie N, Yu Y, Xu X, Hu H, Yao H. Xu Y, et al. Among authors: xu x. Cancer Res. 2022 Feb 15;82(4):556-570. doi: 10.1158/0008-5472.CAN-21-1446. Cancer Res. 2022. PMID: 34965935 Free PMC article.

9

LCDR regulates the integrity of lysosomal membrane by hnRNP K-stabilized LAPTM5 transcript and promotes cell survival.

Yang X, Wen Y, Liu S, Duan L, Liu T, Tong Z, Wang Z, Gu Y, Xi Y, Wang X, Luo D, Zhang R, Liu Y, Wang Y, Cheng T, Jiang S, Zhu X, Yang X, Pan Y, Cheng S, Ye Q, Chen J, Xu X, Gao S. Yang X, et al. Among authors: xu x. Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):e2110428119. doi: 10.1073/pnas.2110428119. Proc Natl Acad Sci U S A. 2022. PMID: 35091468 Free PMC article.

10

Silencing LCN2 suppresses oral squamous cell carcinoma progression by reducing EGFR signal activation and recycling.

Huang Z, Rui X, Yi C, Chen Y, Chen R, Liang Y, Wang Y, Yao W, Xu X, Huang Z. Huang Z, et al. Among authors: xu x. J Exp Clin Cancer Res. 2023 Mar 11;42(1):60. doi: 10.1186/s13046-023-02618-z. J Exp Clin Cancer Res. 2023. PMID: 36899380 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

53,740 results

Search Page